Susceptibility_NN of_IN Human_NP Hepatitis_NP Delta_NP Virus_NP RNAs_NP to_TO Small_NP Interfering_NP RNA_NP Action_NP In_IN animal_JJ cells_NNS ,_, small_JJ interfering_VBG RNAs_NP (_( siRNA_NP )_) ,_, when_WRB exogenously_RB provided_VBN ,_, have_VBP been_VBN reported_VBN to_TO be_VB capable_JJ of_IN inhibiting_VBG replication_NN of_IN several_JJ different_JJ viruses_NNS ._SENT In_IN preliminary_JJ studies_NNS ,_, siRNA_NN species_NNS were_VBD designed_VBN and_CC tested_VBN for_IN their_PP$ ability_NN to_TO act_VB on_IN the_DT protein_NN expressed_VBN in_IN Huh7_JJ cells_NNS transfected_VBN with_IN DNA-directed_NP mRNA_NP constructs_VBZ containing_VBG hepatitis_NN delta_NN virus_NN (_( HDV_NP )_) target_NN sequences_NNS ._SENT The_DT aim_NN was_VBD to_TO achieve_VB siRNA_NN specific_JJ for_IN each_DT of_IN the_DT three_CD RNAs_NP of_IN HDV_NP replication_NN :_: (_( i_NP )_) the_DT 1,679-nucleotide_NN circular_JJ RNA_NP genome_NN ,_, (_( ii_NNS )_) its_PP$ exact_JJ complement_NN ,_, the_DT antigenome_NN ,_, and_CC (_( iii_NNS )_) the_DT less_RBR abundant_JJ polyadenylated_JJ mRNA_NN for_IN the_DT small_JJ delta_NN protein_NN ._SENT Many_JJ of_IN the_DT 16_CD siRNA_NN tested_VBN gave_VBD >80_JJ %_NN inhibition_NN in_IN this_DT assay_NN ._SENT Next_RB ,_, these_DT three_CD classes_NNS of_IN siRNA_NN were_VBD tested_VBN for_IN their_PP$ ability_NN to_TO act_VB during_IN HDV_NP genome_NN replication_NN ._SENT It_PP was_VBD found_VBN that_IN only_JJ siRNA_NN targeted_VBN against_IN HDV_NP mRNA_NP sequences_NNS could_MD interfere_VB with_IN HDV_NP genome_NN replication_NN ._SENT In_IN contrast_NN ,_, siRNA_NN targeted_VBN against_IN genomic_JJ and_CC antigenomic_JJ RNA_NP sequences_NNS had_VBD no_DT detectable_JJ effect_NN on_IN the_DT accumulation_NN of_IN these_DT RNAs_NP ._SENT Reconstruction_NN experiments_NNS with_IN nonreplicating_VBG HDV_NP RNA_NP sequences_NNS support_VBP the_DT interpretation_NN that_IN neither_CC the_DT potential_NN for_IN intramolecular_JJ rod-like_JJ RNA_NP folding_NN nor_CC the_DT presence_NN of_IN the_DT delta_JJ protein_NN conferred_VBD resistance_NN to_TO siRNA_NN ._SENT In_IN terms_NNS of_IN replicating_VBG HDV_NP RNAs_NP ,_, it_PP is_VBZ considered_VBN more_RBR likely_JJ that_IN the_DT genomic_JJ and_CC antigenomic_JJ RNAs_NNS are_VBP resistant_JJ because_IN their_PP$ location_NN within_IN the_DT nucleus_NN makes_VBZ them_PP inaccessible_JJ to_TO siRNA-mediated_JJ degradation_NN ._SENT Human_NP hepatitis_NP delta_NN virus_NN (_( HDV_NP )_) has_VBZ a_DT 1,679-nucleotide_NN (_( nt_JJ )_) single-stranded_JJ circular_JJ RNA_NP genome_NN that_WDT is_VBZ replicated_VBN by_IN RNA-directed_NP RNA_NP synthesis_NN ,_, most_RBS probably_RB involving_VBG host_NN RNA_NP polymerase_NN II_NP ._SENT During_IN this_DT replication_NN ,_, three_CD RNA_NP species_NNS accumulate_VBP ,_, as_RB represented_VBN in_IN Fig._NN ._SENT The_DT genome_NN and_CC its_PP$ exact_JJ complement_NN ,_, the_DT antigenome_NN ,_, are_VBP considered_VBN unit_NN length_NN ._SENT They_PP exist_VBP primarily_RB in_IN a_DT circular_JJ conformation_NN but_CC also_RB in_IN a_DT linear_JJ conformation_NN ;_: these_DT two_CD conformations_NNS can_MD be_VB resolved_VBN using_VBG appropriate_JJ conditions_NNS of_IN gel_NN electrophoresis_NN ._SENT The_DT third_JJ RNA_NP species_NN consists_VBZ of_IN relatively_RB lower_JJR amounts_NNS of_IN an_DT 800-nt_JJ polyadenylated_JJ RNA_NP (_( of_IN the_DT same_JJ polarity_NN as_IN the_DT antigenome_NN )_) ,_, which_WDT is_VBZ translated_VBN to_TO produce_VB a_DT 195-amino-acid_JJ protein_NN ,_, known_VBN as_IN the_DT delta_JJ antigen_NN (_( deltaAg-S_NNS )_) ,_, and_CC is_VBZ essential_JJ for_IN HDV_NP genome_NN replication_NN ._SENT An_DT increasing_VBG number_NN of_IN reports_NNS have_VBP shown_VBN that_IN small_JJ interfering_VBG RNAs_NP (_( siRNA_NP )_) can_MD be_VB exogenously_RB provided_VBN to_TO cells_NNS undergoing_VBG animal_JJ virus_NN replication_NN and_CC achieve_VB inhibition_NN ._SENT For_IN the_DT following_VBG reasons_NNS ,_, we_PP were_VBD specifically_RB interested_JJ in_IN the_DT possible_JJ susceptibility_NN to_TO siRNA_NN of_IN HDV_NP RNAs_NP ._SENT (_( i_NP )_) The_DT HDV_NP genomic_JJ and_CC antigenomic_JJ RNAs_NP can_MD fold_VB into_IN an_DT unbranched_JJ rod-like_JJ structure_NN with_IN 74_CD %_NN of_IN the_DT bases_NNS paired_VBN ,_, and_CC this_DT folding_NN might_MD interfere_VB with_IN siRNA_NN action_NN ._SENT (_( ii_NP )_) The_DT delta_JJ protein_NN has_VBZ the_DT ability_NN to_TO bind_VB double-stranded_JJ RNA_NP and_CC thus_RB might_MD also_RB interfere_VB ._SENT (_( iii_NP )_) While_IN several_JJ reports_NNS indicate_VBP that_IN HDV_NP genomic_JJ and_CC antigenomic_JJ RNAs_NNS are_VBP predominantly_RB located_VBN in_IN the_DT cell_NN nucleus_NN ,_, two_CD recent_JJ studies_NNS using_VBG cell_NN fractionation_NN indicated_VBD that_IN much_RB of_IN the_DT genomic_JJ RNA_NP (_( but_CC not_RB the_DT antigenomic_NP RNA_NP )_) might_MD be_VB cytoplasmic_JJ and_CC thus_RB possibly_RB accessible_JJ to_TO siRNA_NN attack_NN ._SENT With_IN these_DT questions_NNS in_IN mind_NN ,_, our_PP$ first_JJ objective_NN was_VBD to_TO design_VB and_CC test_VB siRNA_NN species_NNS specific_JJ for_IN sequences_NNS on_IN HDV_NP mRNA_NP ,_, genomic_JJ RNA_NP ,_, and_CC antigenomic_NP RNA_NP ._SENT As_IN represented_VBN in_IN Fig._NN ,_, the_DT initial_JJ strategy_NN was_VBD to_TO use_VB expression_NN vectors_NNS to_TO produce_VB within_IN Huh7_JJ cells_NNS DNA-directed_JJ mRNA_NN species_NNS that_WDT contain_VBP these_DT three_CD sequences_NNS ._SENT As_IN indicated_VBN ,_, a_DT total_NN of_IN 16_CD siRNA_NN ,_, each_DT containing_VBG a_DT 21-nt_JJ region_NN based_VBN on_IN the_DT nucleotide_NN sequence_NN of_IN Kuo_NP et_FW al._FW ,_, were_VBD designed_VBN and_CC constructed_VBN using_VBG a_DT Silencer_NP siRNA_NN construction_NN kit_NN (_( Ambion_NP )_) ._SENT The_DT locations_NNS and_CC sequences_NNS of_IN the_DT target_NN sites_NNS are_VBP listed_VBN in_IN Table_NP ._SENT The_DT assay_NN in_IN each_DT case_NN was_VBD for_IN the_DT translation_NN and_CC accumulation_NN of_IN the_DT delta_JJ protein_NN ,_, as_RB detected_VBN by_IN immunoblotting_NN ._SENT The_DT results_NNS and_CC their_PP$ quantitation_NN are_VBP presented_VBN in_IN Fig._NN ._SENT Also_RB shown_VBN is_VBZ the_DT immunoblot_NN for_IN the_DT internal_JJ control_NN ,_, green_JJ fluorescent_JJ protein_NN (_( GFP_NP )_) ._SENT An_DT expression_NN vector_NN for_IN GFP_NP was_VBD cotransfected_VBN ,_, and_CC as_RB expected_VBN ,_, the_DT siRNA_NN directed_VBN against_IN HDV_NP sequences_NNS did_VBD not_RB inhibit_VB the_DT accumulation_NN of_IN GFP_NP protein_NN ._SENT Consistent_JJ with_IN the_DT siRNA_NN experience_NN of_IN others_NNS ,_, we_PP found_VBD that_IN some_DT of_IN the_DT designed_VBN siRNA_NN were_VBD able_JJ to_TO give_VB 80_CD to_TO 95_CD %_NN inhibition_NN of_IN the_DT HDV_NP mRNA_NN sequences_NNS (_( Fig._NN ,_, lanes_NNS 4_CD ,_, 6_CD ,_, and_CC 7_CD )_) ._SENT Furthermore_RB ,_, as_IN planned_VBN ,_, it_PP was_VBD possible_JJ to_TO obtain_VB siRNA_NN that_WDT attacked_VBD the_DT genomic_JJ and_CC antigenomic_JJ RNA_NP sequences_NNS (_( Fig._NN ,_, respectively_RB )_) ._SENT It_PP should_MD be_VB noted_VBN that_IN in_IN Fig._NN ,_, the_DT insert_NN of_IN 657_CD nt_NNS of_IN antigenomic_JJ sequence_NN (_( from_IN position_NN 660_CD to_TO 4_CD )_) should_MD thus_RB have_VB been_VBN able_JJ in_IN large_JJ part_NN to_TO fold_VB with_IN the_DT 585_CD nt_NNS spanning_VBG the_DT delta_JJ antigen_NN open_JJ reading_NN frame_NN (_( at_IN position_NN 1596_CD to_TO 1011_CD )_) into_IN an_DT extensive_JJ amount_NN of_IN unbranched_JJ rod-like_JJ structure_NN ._SENT Even_RB if_IN this_DT potential_JJ folding_NN did_VBD occur_VB in_IN vivo_RB ,_, it_PP did_VBD not_RB confer_VB resistance_NN to_TO functioning_VBG siRNA_NN (_( lanes_NNS 14_CD ,_, 15_CD ,_, and_CC 16_CD )_) ._SENT We_PP next_RB examined_VBD whether_IN those_DT siRNA_NN with_IN proven_JJ activity_NN could_MD interfere_VB with_IN HDV_NP genome_NN replication_NN ,_, as_RB assayed_VBN by_IN the_DT accumulation_NN of_IN unit-length_NN HDV_NP RNA_NP species_NNS ._SENT Some_DT results_NNS are_VBP shown_VBN in_IN Fig._NN ,_, along_RB with_IN quantitation_NN ._SENT We_PP observed_VBD that_DT inhibition_NN of_IN RNA_NP accumulation_NN occurred_VBD only_RB with_IN siRNA_NP 4_CD and_CC 6_CD ,_, which_WDT targeted_VBD the_DT mRNA_NN sequences_NNS and_CC caused_VBD a_DT significant_JJ reduction_NN of_IN delta_JJ protein_NN accumulation_NN ._SENT (_( In_IN panel_NN A_NP ,_, the_DT data_NNS shown_VBN are_VBP for_IN antigenomic_JJ RNA_NP ;_: however_RB ,_, similar_JJ results_NNS were_VBD obtained_VBN for_IN genomic_JJ RNA_NP [_SYM data_NN not_RB shown_VBN ]_SYM ._SENT Also_RB ,_, siRNA_NP 14_CD ,_, 15_CD ,_, and_CC 16_CD failed_VBN to_TO reduce_VB HDV_NP RNA_NP accumulation_NN ._SENT )_) In_IN the_DT above-described_JJ experiment_NN ,_, the_DT gel_NN electrophoresis_NN conditions_NNS used_VBN do_VBP not_RB separate_VB the_DT circular_NN from_IN the_DT linear_JJ conformations_NNS of_IN unit-length_NN HDV_NP RNAs_NP ._SENT However_RB ,_, if_IN the_DT siRNA_NN treatment_NN led_VBN to_TO single_JJ endonucleolytic_JJ cuts_NNS on_IN unit-length_NN circles_NNS to_TO produce_VB linears_NNS ,_, we_PP expect_VBP that_IN this_DT would_MD have_VB inhibited_VBN further_JJR RNA_NP accumulation_NN ._SENT Therefore_RB ,_, to_TO further_RBR test_VB this_DT preliminary_JJ interpretation_NN that_IN unit-length_JJ genomic_JJ and_CC antigenomic_JJ RNAs_NP were_VBD resistant_JJ to_TO siRNA_NN ,_, we_PP carried_VBD out_RP the_DT following_VBG additional_JJ experiment_NN ._SENT We_PP used_VBD transfection_NN to_TO express_VB HDV_NP RNA_NP multimers_NNS by_IN DNA-directed_NP RNA_NP transcription_NN ._SENT From_IN previous_JJ studies_NNS ,_, we_PP knew_VBD that_IN these_DT would_MD be_VB posttranscriptionally_RB processed_VBN to_TO form_VB unit-length_JJ RNA_NP circles_NNS and_CC yet_RB ,_, because_IN of_IN a_DT 2-nt_JJ deletion_NN in_IN the_DT open_JJ reading_NN frame_NN for_IN the_DT small_JJ delta_NN protein_NN ,_, would_MD be_VB unable_JJ to_TO make_VB the_DT essential_JJ delta_NN protein_NN and_CC undergo_VB RNA-directed_JJ transcription_NN and_CC replication_NN ._SENT We_PP then_RB used_VBD gel_NN analysis_NN conditions_NNS capable_JJ of_IN separating_VBG both_DT linear_JJ and_CC circular_JJ conformations_NNS of_IN unit-length_NN HDV_NP RNA_NP ._SENT Some_DT data_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT As_RB can_MD be_VB seen_VBN from_IN the_DT quantitation_NN ,_, cotransfection_NN with_IN siRNA_NP 10_CD ,_, 11_CD ,_, 12_CD ,_, and_CC 13_CD ,_, specific_JJ for_IN genomic_JJ RNA_NP sequences_NNS ,_, did_VBD not_RB reduce_VB the_DT accumulation_NN of_IN unit-length_NN genomic_JJ RNA_NP ._SENT Furthermore_RB ,_, the_DT presence_NN of_IN this_DT siRNA_NN did_VBD not_RB cause_VB a_DT reduction_NN in_IN the_DT fraction_NN of_IN RNAs_NP with_IN a_DT circular_JJ conformation_NN (_( lanes_NNS 10_CD to_TO 13_CD relative_NN to_TO lane_NN C_NP )_) ._SENT In_IN similar_JJ experiments_NNS ,_, we_PP expressed_VBD antigenomic_JJ nonreplicating_NN RNAs_NP and_CC found_VBD that_IN they_PP were_VBD not_RB sensitive_JJ to_TO siRNA_NP 4_CD ,_, 6_CD ,_, and_CC 9_CD (_( data_NNS not_RB shown_VBN )_) ._SENT We_PP interpret_VBP these_DT data_NNS as_IN evidence_NN against_IN siRNA_NN action_NN ,_, even_RB for_IN inducing_VBG a_DT single_JJ nick_NN on_IN the_DT nonreplicating_JJ HDV_NP RNAs_NP ._SENT In_IN addition_NN ,_, the_DT delta_JJ protein_NN was_VBD not_RB present_JJ and_CC thus_RB could_MD not_RB be_VB the_DT basis_NN for_IN the_DT observed_JJ resistance_NN ._SENT Our_PP$ studies_NNS show_VBP that_IN HDV_NP circular_JJ RNAs_NP ,_, whether_IN transcribed_VBN from_IN an_DT RNA_NP template_NN or_CC from_IN a_DT DNA_NP template_NN ,_, were_VBD resistant_JJ to_TO siRNA_NN attack_NN ._SENT In_IN the_DT case_NN of_IN the_DT DNA-directed_JJ transcript_NN ,_, the_DT expression_NN vector_NN was_VBD such_JJ that_IN the_DT primary_JJ (_( nonreplicating_JJ )_) multimeric_JJ transcript_NN was_VBD via_IN host_NN RNA_NP polymerase_NN II_NP and_CC that_DT RNA_NP (_( prior_RB to_TO ribozyme_NN processing_NN and_CC ligation_NN to_TO form_VB unit-length_NN circles_NNS )_) should_MD have_VB undergone_VBN both_DT 5'-capping_NN and_CC 3_CD '_'' polyadenylation_NN ._SENT Others_NNS have_VBP shown_VBN that_IN for_IN a_DT host_NN mRNA_NN precursor_NN ,_, the_DT intronic_JJ regions_NNS are_VBP resistant_JJ to_TO siRNA_NN while_IN the_DT exons_NNS are_VBP sensitive_JJ ._SENT Our_PP$ studies_NNS show_VBP that_IN the_DT unit-length_NN circular_NN RNA_NP processed_VBD out_RP of_IN the_DT multimeric_JJ transcript_NN was_VBD not_RB only_RB stable_JJ but_CC also_RB resistant_JJ to_TO siRNA_NN attack_NN ._SENT In_IN summary_NN ,_, these_DT studies_NNS support_VBP the_DT interpretation_NN that_IN during_IN genome_NN replication_NN ,_, the_DT only_JJ HDV_NP RNA_NP directly_RB susceptible_JJ to_TO inhibition_NN mediated_VBD by_IN siRNA_NN is_VBZ the_DT mRNA_NN ._SENT At_IN least_JJS under_IN the_DT conditions_NNS of_IN these_DT experiments_NNS ,_, the_DT resistance_NN of_IN the_DT genomic_JJ and_CC antigenomic_JJ RNAs_NP was_VBD not_RB dependent_JJ on_IN RNA_NP structure_NN ,_, RNA_NP conformation_NN ,_, or_CC the_DT presence_NN of_IN the_DT small_JJ delta_NN protein_NN ._SENT Further_JJR experiments_NNS will_MD be_VB needed_VBN to_TO determine_VB if_IN this_DT "_`` resistance_NN "_'' was_VBD in_IN fact_NN due_JJ to_TO inaccessibility_NN based_VBN on_IN nuclear_JJ localization_NN of_IN genomic_JJ and_CC antigenomic_JJ unit-length_NN RNAs_NP ._SENT It_PP remains_VBZ possible_JJ that_IN some_DT of_IN the_DT genomic_JJ RNA_NP is_VBZ cytoplasmic_JJ but_CC is_VBZ somehow_RB inaccessible_JJ to_TO attack_VB by_IN siRNA_NN ._SENT For_IN example_NN ,_, it_PP could_MD be_VB protected_VBN by_IN a_DT host_NN RNA-binding_NN protein_NN ._SENT For_IN this_DT or_CC maybe_RB other_JJ reasons_NNS ,_, these_DT HDV_NP RNAs_NP are_VBP probably_RB resistant_JJ to_TO siRNA_NN because_IN they_PP are_VBP simply_RB not_RB accessible_JJ to_TO the_DT RISC_NP ,_, a_DT protein-RNA_NN effector_NN nuclease_NN complex_NN that_WDT recognizes_VBZ and_CC destroys_VBZ target_NN RNAs_NP ._SENT In_IN this_DT respect_NN ,_, our_PP$ findings_NNS with_IN HDV_NP are_VBP analogous_JJ to_TO those_DT reported_VBN for_IN siRNA_NN action_NN on_IN the_DT replication_NN of_IN respiratory_JJ syncytial_JJ virus_NN and_CC influenza_NN virus_NN ._SENT That_DT is_VBZ ,_, siRNA_NNS cannot_MD target_VB the_DT replicating_VBG viral_JJ RNA_NP transcripts_NNS directly_RB but_CC only_RB indirectly_RB via_IN action_NN on_IN the_DT viral_JJ mRNA_NN species_NNS ._SENT Representation_NN of_IN three_CD main_JJ species_NNS of_IN HDV_NP RNA_NP ._SENT Representation_NN of_IN three_CD main_JJ species_NNS of_IN HDV_NP RNA_NP ._SENT Also_RB indicated_VBN are_VBP the_DT genomic_JJ and_CC antigenomic_JJ ribozymes_NNS (_( cleavage_NN site_NN is_VBZ shown_VBN as_IN a_DT circle_NN )_) and_CC the_DT open_JJ reading_NN frame_NN (_( ORF_NP )_) for_IN the_DT deltaAg_NN ._SENT At_IN the_DT right_NN is_VBZ the_DT number_NN of_IN molecules_NNS of_IN each_DT RNA_NP per_IN average_JJ liver_NN cell_NN for_IN an_DT infected_JJ woodchuck_NN and_CC chimpanzee_NN ,_, as_RB previously_RB reported_VBN ._SENT Indicated_VBN on_IN the_DT 1,679-nt_JJ genomic_JJ RNA_NP is_VBZ the_DT origin_NN for_IN the_DT nucleotide_NN numbering_VBG ,_, according_VBG to_TO the_DT sequence_NN of_IN Kuo_NP et_FW al._FW ._SENT Transfected_JJ siRNAs_NNS could_MD target_VB HDV_NP mRNA_NN species_NNS ._SENT Transfected_JJ siRNAs_NNS could_MD target_VB HDV_NP mRNA_NN species_NNS ._SENT Huh7_JJ cells_NNS were_VBD transfected_VBN with_IN one_CD of_IN three_CD plasmids_NNS that_WDT express_VBP an_DT HDV_NP mRNA_NN species_NNS ._SENT (_( A_NP )_) pDL444_NN expressed_VBD an_DT mRNA_NN equivalent_NN to_TO normal_JJ HDV_NP mRNA_NP ._SENT (_( B_NP and_CC C_NP )_) pDL444_NN was_VBD modified_VBN to_TO contain_VB 657_CD nt_NN of_IN extra_JJ sequences_NNS in_IN the_DT 3_CD '_POS untranslated_JJ region_NN ,_, which_WDT led_VBD to_TO the_DT transcription_NN of_IN either_DT partial_JJ genomic_JJ HDV_NP RNA_NP sequences_NNS (_( position_NN 4_CD to_TO 660_CD )_) (_( B_NP )_) or_CC antigenomic_JJ RNA_NP sequences_NNS (_( position_NN 660_CD to_TO 4_CD )_) (_( C_NP )_) ._SENT The_DT constructs_NNS were_VBD cotransfected_VBN with_IN a_DT plasmid_NN expressing_VBG GFP_NP ._SENT After_IN 2_CD days_NNS the_DT total_JJ protein_NN was_VBD extracted_VBN and_CC examined_VBN by_IN immunoblotting_VBG to_TO detect_VB both_DT delta_JJ protein_NN and_CC GFP_NP ._SENT Detection_NN and_CC quantitation_NN were_VBD with_IN a_DT bioimager_NN (_( Fuji_NP )_) ._SENT The_DT 16_CD HDV-specific_NP siRNA_NN indicated_VBD in_IN the_DT figure_NN were_VBD designed_VBN and_CC delivered_VBN as_IN a_DT cotransfection_NN using_VBG Lipofectamine_NP 2000_CD (_( Invitrogen_NP )_) ._SENT As_IN a_DT negative_JJ control_NN (_( lanes_NNS C_NN )_) we_PP used_VBD siRNA_NN against_IN glyceraldehyde-3-phosphate_NN dehydrogenase_NN ._SENT Effect_NN of_IN transfected_JJ siRNA_NN on_IN the_DT accumulation_NN of_IN replicating_VBG HDV_NP RNAs_NP ._SENT Effect_NN of_IN transfected_JJ siRNA_NN on_IN the_DT accumulation_NN of_IN replicating_VBG HDV_NP RNAs_NP ._SENT Cells_NNS were_VBD transfected_VBN with_IN pDL553_NN to_TO initiate_VB HDV_NP genome_NN replication_NN ._SENT siRNA_NN species_NNS (_( at_IN 30_CD nM_NN )_) were_VBD cotransfected_VBN as_IN indicated_JJ and_CC as_RB previously_RB described_VBN in_IN Fig._NN ._SENT At_IN day_NN 2_CD ,_, total_JJ RNA_NP was_VBD extracted_VBN ,_, glyoxalated_JJ ,_, and_CC analyzed_VBD by_IN electrophoresis_NN in_IN a_DT 1_CD %_NN agarose_NN gel_NN ._SENT HDV_NP antigenomic_NP RNA_NP was_VBD then_RB detected_VBN by_IN Northern_JJ assay_NN (_( A_NP )_) ._SENT Similarly_RB ,_, total_JJ protein_NN was_VBD examined_VBN by_IN immunoblotting_VBG to_TO detect_VB deltaAg-S_NNS (_( B_NP )_) ._SENT For_IN both_DT panels_NNS ,_, bioimager_NN data_NNS were_VBD subjected_VBN to_TO quantitation_NN ,_, expressing_VBG the_DT amount_NN of_IN signal_NN detected_VBD relative_JJ to_TO that_DT obtained_VBN for_IN the_DT control_NN transfection_NN ._SENT As_IN a_DT negative_JJ control_NN (_( lane_NN C_NP )_) ,_, we_PP used_VBD siRNA_NN against_IN endogenous_JJ glyceraldehyde-3-phosphate_NN dehydrogenase_NN (_( GAPDH_NP )_) ;_: treatment_NN with_IN this_DT siRNA_NN reduced_VBN GAPDH_NP mRNA_NN but_CC had_VBD no_DT effect_NN on_IN HDV_NP RNA_NP levels_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Also_RB shown_VBN in_IN panel_NN B_NN is_VBZ the_DT immunoblot_NN assay_NN for_IN expression_NN of_IN GFP_NP ,_, which_WDT was_VBD cotransfected_VBN as_IN a_DT control_NN ._SENT Transfected_NP siRNA_NP did_VBD not_RB target_VB nonreplicating_JJ unit-length_NN HDV_NP genomic_JJ RNA_NP ._SENT Transfected_NP siRNA_NP did_VBD not_RB target_VB nonreplicating_JJ unit-length_NN HDV_NP genomic_JJ RNA_NP ._SENT Cells_NNS were_VBD transfected_VBN with_IN pDL542_NN to_TO achieve_VB the_DT transcription_NN and_CC accumulation_NN of_IN nonreplicating_VBG unit-length_NN genomic_JJ HDV_NP RNA_NP circles_VBZ ._SENT Cotransfected_JJ with_IN this_DT plasmid_NN was_VBD either_RB a_DT glyceraldehyde-3-phosphate_NN dehydrogenase_NN control_NN siRNA_NN (_( lane_NN C_NP )_) or_CC genomic_JJ HDV-specific_JJ siRNA_NN (_( lanes_NNS 10_CD to_TO 13_CD )_) ,_, as_RB indicated_VBN at_IN the_DT top_NN of_IN the_DT figure_NN and_CC as_RB previously_RB described_VBN for_IN Fig._NN ._SENT At_IN day_NN 2_CD ,_, total_JJ RNA_NP was_VBD extracted_VBN ,_, glyoxalated_JJ ,_, and_CC analyzed_VBD by_IN electrophoresis_NN in_IN a_DT 3_CD %_NN agarose_NN gel_NN ._SENT Linear_NP and_CC circular_JJ forms_NNS of_IN HDV_NP genomic_JJ RNA_NP were_VBD then_RB detected_VBN by_IN Northern_JJ assay_NN ._SENT After_IN hybridization_NN and_CC quantitation_NN using_VBG the_DT bioimager_NN ,_, we_PP deduced_VBD the_DT amounts_NNS of_IN linear_JJ and_CC circular_JJ RNAs_NP ,_, as_RB summarized_VBN in_IN the_DT histogram_NN ._SENT Locations_NNS and_CC sequences_NNS of_IN siRNA_NN targets_NNS 